Jobs with Startups
JobsStartupsInvestorsMCP
Startups

Harmonic Discovery

Harmonic Discovery logo

Harmonic Discovery

Multi-targeted therapeutics to treat complex diseases

harmonicdiscovery.com
HQ: New York, NY, USA; Remote
1-10
Healthcare

Company research

Public company, workplace, funding, and market signals

Overview

Harmonic Discovery is a New York-based precision pharmacology biotech using machine learning, structural bioinformatics, and generative chemistry to design multi-target kinase therapeutics and partner on drug discovery and licensing programs.

Primary product

An experimentally validated precision pharmacology platform for kinase drug discovery, including its generative chemistry and selectivity tools (Banyan, Kanopy, Terra) and lead preclinical program HD-10019.

Founded

2021

Headquarters

JLABS@NYC, New York City, New York, United States

Team size

1-10

Work style

Remote

Industry

Biotechnology Research

Sub-industry

Precision pharmacology / kinase drug discovery

Offices

JLABS@NYC, New York City, New York, United States

Business model

proprietary therapeutics development
drug discovery platform
biotech/pharma collaboration and licensing

Funding

Stage

seed

Total raised

$8.1M

Latest round

Incubator/Accelerator - IV · Sep 2025

People & investors

Leadership

Rayees Rahman

Founder & Chief Executive Officer

Marcel Patek

Founder & Chief Scientific Officer

Anna Cichońska

Director of Data Science and Head of European Operations

Guru Ravikumar

Director of Chemical Informatics

Founders

Jason Lee

Co-founder & COO

Investors

Boom Capital
Caffeinated Capital
DayOne Accelerator
Fifty Years
Google for Startups Accelerator: Cloud
Hub71 Access Programme
Innovation Endeavors
Y Combinator

Work & culture

Interdisciplinary, science-driven, and collaborative; the company describes its team as passionate innovators, radical thinkers, and collaborative builders, with a remote-first US work setup and regular company off-sites.

Work style

Remote

Compensation

Publicly advertised compensation is competitive salary plus equity, a 401(k) match up to 4%, and a five-week PTO package with a holiday bonus; no public salary bands were found.

Benefits

competitive salary
equity compensation
401(k) with up to 4% match
medical insurance
dental insurance
vision insurance
five weeks PTO
holiday bonus equal to 50% of PTO value
quarterly company off-sites
quarterly excursions

Product & market

Pricing

Custom collaboration/licensing agreements; no public pricing published.

Differentiators

  • —machine learning-first precision pharmacology platform
  • —focus on tuning out toxic off-targets and tuning in beneficial secondary targets
  • —multi-target kinase drug discovery rather than single-target design
  • —proprietary multimodal data integration across sequence, structure, and expression
  • —experimentally validated platform with named internal tools (Banyan, Kanopy, Terra)
  • —strong emphasis on kinome-wide selectivity and anti-target avoidance

Technology

machine learning
deep learning
structural bioinformatics
generative chemistry
graph neural networks
multimodal data
Direct Preference Optimization
AlphaFold2-predicted structures
protein-ligand 3D modeling
kinome-wide selectivity prediction
chemogenomics
bioactivity prediction
proprietary data

Customers

biotechnology companies
pharmaceutical companies
academic drug-discovery collaborators

Competitors

Jazz Pharmaceuticals
Sana Biotechnology
C4 Therapeutics
Turbine

Scale & contact

Estimated revenue

under $1M

Estimated monthly visits

825

pr@harmonicdiscovery.com

Latest news

Why hasn’t AI in Drug Discovery had its ChatGPT moment?

Harmonic Discovery (Medium) · Aug 2024

Company blog post discussing data challenges and the case for explainable, data-rich AI in drug discovery; written by Anna Cichońska and Rayees Rahman.

Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy

Business Wire · Apr 2024

Harmonic Discovery announced a collaboration with Turbine to co-develop a novel cancer therapy using simulation-guided biology and its multi-target kinase chemistry platform.

Harmonic Discovery Announces Licensing Agreement with BioVentures and UCSF for FLT3 Mutated AML Development Program

PR Newswire · Jan 2024

Harmonic Discovery announced an exclusive licensing agreement for HD-10019, a novel small-molecule candidate for FLT3-mutated AML, and said preclinical development was underway.

harmonic discovery launches with $8 million in seed to develop a new generation of multi-target kinase inhibitors

Harmonic Discovery (Medium) · Sep 2022

Company launch post announcing $8 million seed funding led by Innovation Endeavors with participation from Fifty Years, Y Combinator, Boom Capital, Caffeinated Capital, and select angel investors.

Introducing Harmonic Discovery

Harmonic Discovery (Medium) · Sep 2022

Founding post describing the mission to embed disease complexity into drug discovery and build a machine-learning-first platform for kinase therapeutics.

CareersGitHubHomepageLinkedIn companyNews / blogPartnershipsPipelinePlatformScienceTeam
SourcesOfficial homepageTeam pageCareers pagePlatform pageScience pagePartnerships pageNews/blog hubGitHub organizationLinkedIn company pageSeed financing press releaseLicensing agreement press releaseTurbine collaboration press releaseIntroducing Harmonic DiscoveryAI in drug discovery blog postCB Insights company profileTracxn company profile

Jobs and careers at Harmonic Discovery

0 jobs at Harmonic Discovery

No open positions

Check back later for new openings

Explore startup hiring

Startup Hiring PulseBrowse all startup jobsJobs at Y Combinator startupsJobs at venture-backed startupsHealthcare startup jobs

Jobs with Startups © 2026

Browse jobsMCP guideAboutPowered by Supabase